AstraZeneca Seeks FDA Approval for New Lung Cancer Treatment

AstraZeneca has applied to the FDA for approval of ORPATHYS-TAGRISSO, a new lung cancer treatment in partnership with HUTCHMED, which could expand the use of Tagrisso and potentially accelerate AstraZeneca’s oncology growth.

Why it matters. AstraZeneca’s potential approval of ORPATHYS could strengthen its oncology franchise and provide a new growth avenue, but the FDA’s review and the narrow patient population are key risks.